Skip to main content Accessibility help
×
Home
  • Print publication year: 2017
  • Online publication date: March 2017

14 - Treatment of Ovarian Hyperstimulation Syndrome

1.Rizk, B, Smitz, J. Ovarian hyperstimulation syndrome after superovulation for IVF and related procedures. Hum Reprod 1992;7:320–27.
2.Rizk, B. Ovarian hyperstimulation syndrome. In: Studd, J, ed. Progress in Obstetrics and Gynecology. Edinburgh: Churchill Livingstone, 1993; Chapter 11, pp. 311–49.
3.Rizk, B, Rizk, C B, Nawar, M G, Garcia-Velasco, J A, Sallam, H N. Ultrasonography in the prediction and management of ovarian hyperstimulation syndome In: Rizk, B, ed. Ultrasonography in Reproductive Medicine and Infertility. Cambridge: Cambridge University Press, 2010, Chapter 36, pp. 299312.
4.Serour, G I, Aboulghar, M A, Mansour, R, et al. Complications of medically assisted conception in 3,500 cycles. Fertil Steril 1998;70:638–42.
5.Mathur, R S, Akande, A V, Keay, S D, et al. Distinction between early and late ovarian hyperstimulation syndrome. Fertil Steril 2000;73:901–07.
6.Aboulghar, M A, Mansour, R T. Ovarian hyperstimulation syndrome: classifications and critical analysis of preventive measures. Hum Reprod Update 2003;9:275–89.
7.Rizk, B, Aboulghar, M A. Classification, pathophysiology and management of ovarian hyperstimulation syndrome. In: Brinsden, P, ed. A Textbook of In-vitro Fertilization and Assisted Reproduction, Second Edition. Carnforth: The Parthenon Publishing Group, 1999, Chapter 11, pp. 131–55.
8.Rizk, B, Aboulghar, M A, Smitz, J, RonEl, R. The role of vascular endothelia growth factor and interleukins in the pathogenesis pf severe ovarian hyperstimulation syndrome Hum Reprod Update 1997;3:255–66.
9.Pellicer, A, Albert, C, Mercader, A, et al. The pathogenesis of ovarian hyperstimulation syndrome: in vivo studies investigating the role of interleukin 1-β, interleukin-6 and vascular endothelial growth factor. Fertil Steril 1999;71:482–89.
10.Rizk, B. Ovarian Hyperstimulation Syndrome: Epidemiology, Pathophysiology, Prevention and Management. Cambridge: Cambridge University Press, 2006.
11.Rizk, B, Aboulghar, M. Modern management of ovarian hyperstimulation syndrome. Hum Reprod 1991;6:1082–87.
12.Delvigne, A, Rozenberg, S. Epidemiology and prevention of ovarian hyperstimulation syndrome (OHSS): a review. Hum Reprod Update 2002;8:559–77.
13.Practice Committee of the American Society for Reproductive Medicine. Ovarian hyperstimulation syndrome. Fertil Steril 2003;80:1309–14.
14.Rizk, B. Prevention of ovarian hyperstimulation syndrome: the Ten Commandments. Presented at the 1993 European Society of Human Reproduction and Embryology Symposium, Tel Aviv, Israel, 1993, 12.
15.Al-Inany, H, Aboulghar, M A, et al. Gonadotropin-releasing hormone antagonists in assisted reproduction: a Cochrane review. Hum Reprod 2002;17:874–85.
16.Ludwig, M, Katalinic, A, Diedrich, K. Use of GnRH antagonists in ovarian stimulation for assisted reproductive technologies compared to the long protocol. Meta-analysis. Arch Gynecol Obstet 2001;265:175–82.
17.Al-Inany, H G, Abou-Setta, A M, Boulghar, M. Gonadotropin-releasing hormone antagonists for assisted conception. Cochrane Database Syst Rev 2011;(5):CD001750.
18.Kolibianakis, E M, Collins, J, Tarlatzis, B C, et al. Among patients treated for IVF with gonadotropins and GnRH analogues, is the probability of live birth dependent on the type of analogue used? A systematic review and meta-analysis. Hum Reprod Update 2006;12:651–71.
19.Rizk, B. Coasting for the prevention of critical OHSS: an American perspective In: Gerris, J, Olivennes, F, Delvigne, A, eds. Ovarian Hyperstimulation Syndrome. Taylor and Francis, 2006; Chapter 23, pp. 247–67.
20.Rizk, B. Prevention and management of ovarian hyperstimulation syndrome. Curr Women’s Health Rev 2010;6(2):130–45.
21.Abdalla, H I, Ahmoye, N M, Brinsden, P, et al. The effect of the dose of human chorionic gonadotrophin and the type of gonadotrophin stimulation on oocyte recovery rates in an in-vitro fertilization program. Fertil Steril 1987; 48:958–63.
22.Tsoumpou, I, Muglu, J, Gelbaya, T A, Nardo, L G. Optimal dose of hCG for final oocyte maturation in IVF cycles: absence of evidence. Reprod Biomed Online 2009;19(1):5258.
23.Griesinger, G, Diedrich, K, Devroey, P, et al. GnRH agonist for triggering final oocyte maturation in the GnRH antagonist ovarian hyperstimulation protocol: a systematic review and meta-analysis. Hum Reprod Update 2006;12:159–68.
24.Aboulghar, M, Evers, J H, Al-Inany, H. Intravenous albumin for preventing severe ovarian hyperstimulation syndrome. Cochrane Database Syst Rev 2000;2:CD001302.
25.Rizk, B, Aboulghar, M A, Mansour, R T, et al. Severe ovarian hyperstimulation syndrome: analytical study of twenty-one cases. Proceedings of the VII World Congress on In-vitro Fertilization and Assisted Precreations, Paris. Hum Reprod 1991:368–69.
26.Tang, T, Glanville, J, Orsi, N, et al. The use of metformin for women with PCOS undergoing IVF treatment. Hum Reprod 2006;21:1416–25.
27.Moll, E, van der Veen, F, van Wely, M. The role of metformin in polycystic ovary syndrome: a systematic review. Hum Reprod Update 2007;13:527–37.
28.Alvarez, C, Marti-Bonmati, L, Novella-Maestre, E. Dopamine agonist cabergoline reduces hemoconcentration and ascites in hyperstimulated women undergoing assisted reproduction. J Clin Endocrinol Metab 2007;92:2931–37.
29.Alvarez, C, Alonso-Muriel, I, Garcia, G, et al. Implantation is apparently unaffected by the dopamine agonist cabergoline when administered to prevent ovarian hyperstimulation syndrome in women undergoing assisted reproduction treatment: a pilot study. Hum Reprod 2007;22:3210–14.
30.Busso, C E, Garcia-Velasco, J A, Gomz, R, et al. Ovarian hyperstimulation syndrome. In: Rizk, B, Garcia-Velasco, J A, Sallam, H N, Makrigiannakis, A, eds. Infertility and Assisted Reproduction. Cambridge: Cambridge University Press, 2008; Chapter 27, pp. 243–57.
31.Busso, C, Fernandez-Sanchez, M, Garcia-Velasco, J A, et al. Quinagolide is effective in preventing moderate/severe early OHSS in IVF patients: a randomized, double blind, placebo, controlled trial. The 24th Annual Mtg of the European Society of Reproduction and Embryology, 6–9 July, Barcelona, Spain, 2008;41(abstract).
32.Busso, C E. Prevention of OHSS-dopamine agonists. Reproductive Biomed Online 2009;19(1):4351.
33.D’Angelo, A, Amso, N. Embryo freezing for preventing ovarian hyperstimulation syndrome: a Cochrane review. Hum Reprod 2002;17:2787–94.
34.Son, W Y, Yoon, S H, Lim, J H. Effect of gonadotropin priming on in-vitro maturation of oocytes collected from women at risk of OHSS. Reprod Biomed Online 2006;13:340–48.
35.Son, W Y, Yoon, S H, Lee, S W, et al. Blastocyst development and pregnancies after IVF of mature oocytes retrieved from unstilulated patients with PCOS after in-vivo hCG priming. Hum Reprod 2002;17:134–36.
36.Abramov, Y, Fatum, M, Abrahomov, D, et al. Hydroxyethyl starch versus human albunin for the treatment of severe ovarian hyperstimulation syndrome: a prelinimary report. Fertil Steril 2001;75:1228–30.
37.Gamzu, R, Almog, B, Levin, Y, et al. Efficacy of hydroxyethyl starch and haemaccel for the treatment of severe ovarian hyperstimulation syndrome. Fertil Steril 2002;77:1302–03.
38.Rizk, B, Meagher, S, Fisher, A M. Ovarian hyperstimulation syndrome and cerebrovascular accidents. Hum Reprod 1990;5:697–98.
39.Brinsden, P R, Wada, I, Tan, S L, et al. Diagnosis, prevention and management of ovarian hyperstimulation syndrome. Br J Obstet Gynaecol 1995;102:767–72.
40.Fabregues, F, Tassies, D, Reverter, J C, et al. Prevalence of thrombophilia in women with severe ovarian hyperstimulation syndrome and cost-effectiveness of screening. Fertil Steril 2004;81:989–95.
41.Mikhail, S, Rizk, R M B, Nawar, M G, Rizk, C B. Thrombophilia and implantation failure. In: Rizk, B, Garcia-Velasco, J A, Sallam, H N, Makrigiannakis, A, eds. Infertility and Assisted Reproduction. Cambridge: Cambridge University Press, 2008; Chapter 45, pp. 407–15.
42.Aboulghar, M A, Mansour, R T, Serour, G I, et al. Ultrasonically guided vaginal aspiration of ascites in the treatment of ovarian hyperstimulation syndrome. Fertil Steril 1990;53:933–35.
43.Aboulghar, M A, Mansour, R T, Serour, G I, et al. Autotransfusion of the ascitic fluid in the treatment of severe ovarian hyperstimulation syndrome (OHSS). Fertil Steril 1992;58:1056–59.
44.Ferraretti, A P, Gianaroli, L, Diotallevi, L, et al. Dopamine treatment for severe hyperstimulation syndrome. Hum Reprod 1992; 7:180–83.
45.Tsunoda, T, Shibahara, H, Hirano, Y, et al. Treatment of ovarian hyperstimulation syndrome using an oral dopamine prodrug, docarpamine. Gynecol Endocrinol 2003;17:281–86.
46.Rizk, B. Complications of ovulation induction II: ovarian hyperstimulation syndrome, ovarian torsion. In: Dickey, R P, Brinsden, P R, Pyrzak, R, eds. Manual of Intrauterine Insemination and Ovulation Induction. Cambridge: Cambridge University Press, 2010; Chapter 15, pp. 152–60.
47.Eyvazzadeh, A D, Ryley, D A, Khachadoorian, H R, Alper, M M, Reindollar, R H. Adnexal torsion: a review of 80 cases. Fertil Steril 2005;84(Suppl 1):S164–65.
48.Aboulghar, M. Prevention of OHSS. RBM Online 2009;19(1):3342.